The gold standard for the treatment of diabetes would be wearable biosensors with improved specificity and sensitivity, and of a low detection limit for the precision delivery, aside from overcoming the challenge of the oral delivery of insulin. The gene discussed is INS; the disease is diabetes mellitus.